Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by whisky11on Apr 27, 2021 11:28am
154 Views
Post# 33074374

RE:RE:RE:Re: Buyout

RE:RE:RE:Re: Buyout AngelaL]Biotech buyouts are typically at a much higher multiplr than in other industries. It would not be surprising to see a 2.5-3.0 fold price over the current sp, especially since Claritas is currently so severely undervalued.

whisky11: yes sp is very much undervalued. And the reason of it is complicated one,what Claritas can't control is lack of buyers with deep pocket.
I heard somewhere else  that 50% of traders take a break during coronavirus.
My scenario would be that the company goes outside with press releases, so far management target us existing shareholders.
Second thinking three or four months from now phase 1 is finished, imagine opportunity with the publicity.
So the stock price then is 1 to 2 dollars and then many suitors will ask us for our vote to sell.


<< Previous
Bullboard Posts
Next >>